CiteULike  View Full Text   View/Add Comment  Download reader    
Peng Zou,Lin Zhao,Haitao Xu,Ping Chen,Aihua Gu,Ning Liu,Peng Zhao,Ailin Lu.Journal of Biomedical Research,2012,26(4):253-259
Hsa-mir-499 rs3746444 polymorphism and cancer risk: a meta-analysis
Received:October 24, 2011  
DOI:10.7555/JBR.26.20110122
Keywordscancer, meta-analysis, hsa-mir-499 rs3746444, polymorphism, susceptibility, miRNAs, pre-miRNA
Grant Program
                       
AuthorInstitution
Peng Zou Department of Neurosurgery, the First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu , China
Lin Zhao Department of Neurosurgery, the First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu , China
Haitao Xu Department of Neurosurgery, the First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu , China
Ping Chen Department of Neurosurgery, the First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu , China
Aihua Gu State Key Laboratory of Reproductive Medicine, Institute of Toxicology, Nanjing Medical University, Nanjing, Jiangsu , China
Ning Liu Department of Neurosurgery, the First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu , China
Peng Zhao Department of Neurosurgery, the First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu , China
Ailin Lu Department of Neurosurgery, the First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu , China
Hits: 1262
Download times: 6
      
Abstract
      MicroRNAs (miRNAs) are gene regulators involved in numerous diseases including cancer, heart disease, neurological disorders, vascular abnormalities and autoimmune conditions. Although hsa-mir-499 rs3746444 polymorphism was shown to contribute to the susceptibility of multiple genes to cancer, the data have yielded conflicting results. Therefore, this meta-analysis was performed to provide a comprehensive assessment of potential association between hsa-mir-499 rs3746444 polymorphism and cancer risk. In this meta-analysis, a total of 9 articles regarding 10 eligible case-control studies in English (including 6134 cases and 7141 controls) were analyzed. No significant association between hsa-mir-499 rs3746444 polymorphism and overall cancer risk was demonstrated. However, an increased risk was observed in the subgroup of breast cancer patients (G allele vs A allele: OR = 1.10, 95% CI = 1.00-1.20; Pheterogeneity = 0.114; I2 = 53.9%) and population-based studies (G allele vs A allele: OR = 1.12, 95% CI = 1.00-1.25; Pheterogeneity = 0.062; I2 = 64.0%). The findings suggested an association be-tween hsa-mir-499 rs3746444 polymorphism and increased risk to breast cancer.
Close